Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KY7S
|
|||
| Former ID |
DCL001201
|
|||
| Drug Name |
ISIS-FXI
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Coagulation defect [ICD-11: 3B10.0; ICD-9: 286] | Phase 2 | [1] | |
| Company |
ISIS Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Factor XI messenger RNA (F11 mRNA) | Target Info | . | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Human Complement System | |||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01713361) Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.